5-substituted indazoles as kinase inhibitors

The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein A, R1, R2, R3 and m, are defined in the description. The present invention relates also to methods of making said compounds, and compositions containing said compounds which are useful for inhibitin...

Full description

Saved in:
Bibliographic Details
Main Authors BAKKER MARGARETHA H. M, PENNING THOMAS D, LI BIQIN, MACK HELMUT, KALVIN DOUGLAS M, GRACIAS VIJAYA J, HOBSON ADRIAN D, TEUSCH NICOLE, GASIECKI ALAN F, SHUAI QI, VASUDEVAN ANIL, GEORGE DAWN M, SARRIS KATHY A, PATEL JYOTI R, JOHNSON ERIC F, AKRITOPOULOU-ZANZE IRINI, LONG ANDREW J, WOODS KEITH W, WAKEFIELD BRIAN D, TURNER SEAN C, WANG LU, MOORE NIGEL S, SWANN, JR. STEVEN L, MICHMERHUIZEN MELISSA J, MIYASHIRO JULIE M, KOVAR PETER J, DJURIC STEVAN W
Format Patent
LanguageEnglish
Published 20.10.2015
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
METALLURGY
ORGANIC CHEMISTRY
Online AccessGet full text

Cover

More Information
Summary:The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein A, R1, R2, R3 and m, are defined in the description. The present invention relates also to methods of making said compounds, and compositions containing said compounds which are useful for inhibiting kinases such as Glycogen Synthase kinase 3 (GSK-3), Rho kinase (ROCK), Janus Kinases (JAK), Cdc7, AKT, PAK4, PLK, CK2, KDR, MK2, JNK1, aurora, pim 1 and nek 2.
Bibliography:Application Number: US201314136359